


REMARKS

Non-elected claims 1-15, 19-23, and 25-46 have been cancelled. Claims 16-18 and 24 have been amended. New claims 47-55 have been added. Support for all the above amendments may be found throughout the specification as originally filed and none of the amendments constitutes new matter. In particular, support for amino acids 1-249 of WT1 can be found on page 52, line 23.

Following this amendment, Claims 16-18, 24, and 47-55 are under examination. Favorable consideration of the present application in view of the above amendment is respectfully requested.

Respectfully submitted,  
Alexander Gaiger et al.  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Julie A. Urvater, Ph.D., Patent Agent  
Registration No. 50,461

Enclosure:  
Postcard

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031  
D:\NrPortbl\iManage\SANDID\304232\_1.DOC



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 1-15, 19-23 and 25-46 have been cancelled.

New claims 47-55 have been added.

Claims 16-18 and 24 have been amended as follows:

16. (Amended) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a ~~pharmaceutical~~ composition comprising:

(a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:2; and

(b) a physiologically acceptable carrier or excipient;  
and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

17. (Amended) A method for enhancing or inducing an immune response in a patient, comprising administering to a patient a ~~pharmaceutical~~ the composition according to ~~any one of claims 12-15~~ 1.

18. (Amended) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a ~~vaccine~~ an immunogenic composition comprising:

(a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T

cell lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:2; and

(b) a non-specific immune response enhancer;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

24. (Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a ~~pharmaceutical~~ composition comprising:

(a) ~~one or more of:~~

NO:2;  
(i) ~~a WT1 polypeptide comprising the polypeptide set forth in SEQ ID~~

(ii) ~~a polynucleotide encoding a WT1 polypeptide; or~~

(iii) ~~an antigen-presenting cell that expresses a WT1 polypeptide; and~~

(b) ~~a physiologically acceptable carrier or excipient;~~

and thereby stimulating and/or expanding T cells in a mammal.